COLIN PUMPHREY: Open Payments
NPI 1447987003 · BERLIN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 36 payments from 12 companies in 2025. Trend: 2023 $1,250 · 2024 $1,464 · 2025 $609
Food & beverage: $609
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $178 |
| ABBVIE INC. | 4 | $73 |
| PFIZER INC. | 4 | $71 |
| Lilly USA, LLC | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Axsome Therapeutics, Inc. | 4 | $43 |
| Antares Pharma, Inc. | 2 | $32 |
| Amgen Inc. | 2 | $32 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $21 |
Products named: Ozempic, MOUNJARO, CAPLYTA, Auvelity, UBRELVY, NURTEC ODT, XYOSTED, Rybelsus.
Industry payments across NJ — which companies pay providers there.
